Your browser doesn't support javascript.
loading
Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer.
Boehm, Kevin M; Aherne, Emily A; Ellenson, Lora; Nikolovski, Ines; Alghamdi, Mohammed; Vázquez-García, Ignacio; Zamarin, Dmitriy; Long Roche, Kara; Liu, Ying; Patel, Druv; Aukerman, Andrew; Pasha, Arfath; Rose, Doori; Selenica, Pier; Causa Andrieu, Pamela I; Fong, Chris; Capanu, Marinela; Reis-Filho, Jorge S; Vanguri, Rami; Veeraraghavan, Harini; Gangai, Natalie; Sosa, Ramon; Leung, Samantha; McPherson, Andrew; Gao, JianJiong; Lakhman, Yulia; Shah, Sohrab P.
Affiliation
  • Boehm KM; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Aherne EA; Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program, New York, NY, USA.
  • Ellenson L; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Nikolovski I; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Alghamdi M; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Vázquez-García I; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Zamarin D; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Long Roche K; Irving Institute for Cancer Dynamics, Columbia University, New York, NY, USA.
  • Liu Y; Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Patel D; Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
  • Aukerman A; Department of Surgical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Pasha A; Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Rose D; Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
  • Selenica P; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Causa Andrieu PI; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Fong C; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Capanu M; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Reis-Filho JS; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Vanguri R; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Veeraraghavan H; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Gangai N; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Sosa R; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Leung S; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • McPherson A; Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Gao J; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Lakhman Y; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Shah SP; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nat Cancer ; 3(6): 723-733, 2022 06.
Article de En | MEDLINE | ID: mdl-35764743
ABSTRACT
Patients with high-grade serous ovarian cancer suffer poor prognosis and variable response to treatment. Known prognostic factors for this disease include homologous recombination deficiency status, age, pathological stage and residual disease status after debulking surgery. Recent work has highlighted important prognostic information captured in computed tomography and histopathological specimens, which can be exploited through machine learning. However, little is known about the capacity of combining features from these disparate sources to improve prediction of treatment response. Here, we assembled a multimodal dataset of 444 patients with primarily late-stage high-grade serous ovarian cancer and discovered quantitative features, such as tumor nuclear size on staining with hematoxylin and eosin and omental texture on contrast-enhanced computed tomography, associated with prognosis. We found that these features contributed complementary prognostic information relative to one another and clinicogenomic features. By fusing histopathological, radiologic and clinicogenomic machine-learning models, we demonstrate a promising path toward improved risk stratification of patients with cancer through multimodal data integration.
Sujet(s)

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs de l'ovaire / Cystadénocarcinome séreux Type d'étude: Etiology_studies / Prognostic_studies / Risk_factors_studies Limites: Female / Humans Langue: En Journal: Nat Cancer Année: 2022 Type de document: Article Pays d'affiliation: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs de l'ovaire / Cystadénocarcinome séreux Type d'étude: Etiology_studies / Prognostic_studies / Risk_factors_studies Limites: Female / Humans Langue: En Journal: Nat Cancer Année: 2022 Type de document: Article Pays d'affiliation: États-Unis d'Amérique
...